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Abstract
A reciprocal translocation involving chromosomes 8 and 21 generates the AML1/ETO oncogenic transcription factor that
initiates acute myeloid leukemia by recruiting co-repressor complexes to DNA. AML1/ETO interferes with the function of its
wild-type counterpart, AML1, by directly targeting AML1 binding sites. However, transcriptional regulation determined by
AML1/ETO probably relies on a more complex network, since the fusion protein has been shown to interact with a number
of other transcription factors, in particular E-proteins, and may therefore target other sites on DNA. Genome-wide chromatin
immunoprecipitation and expression profiling were exploited to identify AML1/ETO-dependent transcriptional regulation.
AML1/ETO was found to co-localize with AML1, demonstrating that the fusion protein follows the binding pattern of the
wild-type protein but does not function primarily by displacing it. The DNA binding profile of the E-protein HEB was grossly
rearranged upon expression of AML1/ETO, and the fusion protein was found to co-localize with both AML1 and HEB on
many of its regulated targets. Furthermore, the level of HEB protein was increased in both primary cells and cell lines
expressing AML1/ETO. Our results suggest a major role for the functional interaction of AML1/ETO with AML1 and HEB in
transcriptional regulation determined by the fusion protein.
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Introduction
Chromosomal translocations generating fusion genes are the
genetic hallmark of Acute Myeloid Leukemia (AML) [1].
Approximately 10–15% of AML cases carry the t(8;21) translo-
cation, which involves the AML1 and ETO genes, and express the
resulting AML1/ETO fusion protein. AML1 is a DNA-binding
transcription factor required for hematopoiesis [2,3] while ETO is
a co-repressor molecule expressed in a variety of tissues [4]. In
hematopoietic cells, the fusion protein determines a stage specific
arrest of maturation and increases cell survival, thus predisposing
to leukemia [5].
Full length AML1/ETO is not sufficient to induce AML in
mice, and requires treatment with mutagens to induce leukemic
transformation [6–9]. An alternatively spliced isoform, AML1/
ETO9a, isolated from AML patients bearing t(8;21), is instead
strongly leukemogenic in mice [10]. AML1/ETO9a includes ETO
exon 9a, which leads to a frameshift of the original coding
sequence and consequently to a C-terminally truncated protein.
Co-expression of AML1/ETO and AML1/ETO9a results in
earlier onset of AML and blocks myeloid cell differentiation at a
more immature stage, suggesting the two isoforms could cooperate
in patients to induce leukemia.
AML1 and AML1/ETO were originally characterized as DNA
binding proteins that recognize, in vitro, the conserved core
sequence TGT/cGGT [11]. A recent study of AML1 and AML1/
ETO binding sites using a 25 bp random oligonucleotide library
revealed that AML1/ETO preferentially binds to DNA sequences
containing multiple AML1 binding sites [12], suggesting the fusion
protein may selectively regulate a subset of AML1 target genes.
AML1/ETO functions as a transcriptional repressor by
recruiting NCoR/SMRT/HDAC complexes to DNA through
its ETO moiety [4] and blocks AML1-dependent transactivation
in various promoter reporter assays, suggesting it may function as
a dominant negative regulator of wild-type AML1 [13–15].
However, AML1/ETO can also induce the expression of specific
target genes: it was initially reported to transactivate M-CSFR and
BCL-2 promoters [16,17] and subsequently, upregulation of other
genes was proposed to be crucial for leukemogenesis [18–20]. The
mechanism for fusion protein-dependent transcriptional activation
is not known.
AML1/ETO was recently hypothesized to target DNA through
E-box motifs as the result of physical interactions with transcrip-
tion factors of the E-protein family, in particular HEB/TCF12
[21]. E-proteins (E2A, HEB, and E2.2) are regulators of
lymphocytic differentiation, and are involved in acute lympho-
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blastic leukemias (ALL) [22,23], while their role in myeloid
differentiation and AML has not, to date, been described.
The large-scale determinants of DNA binding by AML1/ETO
and the correlation to global transcriptional effects remain to be
elucidated. In this study, we present a comprehensive analysis of
the DNA binding pattern of AML1/ETO, and its correlation to
AML1 and HEB binding sites. The fusion protein preferentially
binds to regions that are occupied by the wild-type AML1
transcription factor, without necessarily displacing it. The DNA
binding pattern of HEB is reorganized following AML1/ETO
expression, and the E-protein re-localizes to AML1/ETO binding
regions. Our study provides an accurate description of the
genomic distribution of AML1/ETO, and identifies AML1 and
HEB as crucial elements for its transcriptional regulatory function.
Results
Design of the Study
A U937 cell line that conditionally expresses HA-tagged
AML1/ETO under the control of the mouse metallothionein
(Mt) promoter (U937-AE, [24]) was used for all microarray
experiments. U937-Mt cells, which carry the empty vector, served
as control. Cells were treated with 100 mM ZnSO4 for 8 hours to
induce transgene expression. AML1/ETO protein was expressed
at slightly higher levels than those detected in SKNO-1 cells [25],
which were derived from an AML patient carrying the 8;21
translocation (Figure 1A). SKNO-1 cells were therefore used to
verify the validity of results throughout the study.
Different microarray platforms (Table 1) were exploited to
analyze the DNA binding patterns of AML1/ETO, AML1 and
the E-protein HEB through chromatin immunoprecipitation
(ChIP-chip) and the transcriptional profile of AML1/ETO
expressing cells. First, AML1/ETO binding was measured in
human promoters and correlated with global transcriptional
regulation. Since transcription factors may bind to DNA sequences
far from the promoter, AML1/ETO occupancy was also analyzed
on a high-resolution tiling array, designed to cover an entire
human chromosome. Chromosome 19 (Chr. 19) was chosen due
to its relatively small size and high gene density. Although analysis
of a single chromosome may introduce a bias, and the distribution
of binding sites may be influenced by gene density, these results
can be exploited to infer relevant correlations in the binding
patterns of specific transcription factors. With this aim, the binding
patterns of AML1 and HEB were also analyzed on the Chr. 19
Array. Finally, AML1/ETO-dependent transcriptional regulation
of genes localized on Chr. 19 was measured by hybridization with
total RNA from U937-AE and U937-Mt cells (expression tiling).
Identification of AML1/ETO Binding Sites at Human
Promoters and Correlation with Transcriptional
Regulation
The binding profile of AML1/ETO in human promoters was
investigated through ChIP experiments with an anti-HA antibody
on lysates of U937-AE and U937-Mt cells. ChIP products were
PCR amplified, labeled with Cy3/Cy5 fluorescent dyes and
hybridized to the NimbleGen Systems Human HG17 Promoter
Array set, which explores 4 kb upstream and 1 kb downstream the
transcription start site (TSS) of 24,434 annotated genes. Two
biological replicates were prepared and hybridized to independent
array sets. A proprietary software (PeakPicker, see Text S1) was
used to perform a linear scan across the regions represented on the
array, with the aim of identifying clusters of oligonucleotides with
positive hybridization signals (from now on defined as ‘‘peaks’’).
Specific AML1/ETO binding regions were selected by first
computing all peaks that were present in both experimental
replicas, and then discarding those common to the control sample
(U937-Mt). 2,726 AML1/ETO peaks were identified in the
promoters of 2,513 unique genes, which represent putative targets
of the fusion protein (Table S1).
A group of 22 promoters were analyzed by ChIP coupled with
qPCR (qChIP, [26]) using the anti-HA or anti-ETO antibodies
(ETO protein is not detected in U937 cells). To determine a
reliable baseline, qChIP was also performed in U937-AE cells on 8
promoters that did not display AML1/ETO peaks (Figure S1).
The anti-HA and anti-ETO antibodies yielded identical data and
confirmed the ChIP-chip predictions for 22/22 regions analyzed
(Figure 1B). A parallel qChIP experiment was performed on the
same promoter regions in SKNO-1 cells: AML1/ETO binding
was detected in 17/22 promoters (Figure 1B), suggesting that
ChIP-chip data are representative of the genomic distribution of
the fusion protein in leukemic blasts.
To assess if the truncated AML1/ETO9a isoform interacts with
the same DNA regions as the full length isoform, qChIP was
performed on the same 22 promoters using lysates from a U937
cell line that expresses AML1/ETO9a (U937T-AE9a). The
binding profile of AML1/ETO9a was similar to that of the long
isoform, although relative enrichment levels were not comparable
in all cases (Figure S2). This result suggests that the AML1/
ETO9a isoform binds to the same DNA regions as full length
AML1/ETO, as recently hypothesized based on sequence analysis
of binding sites [12].
Affymetrix GeneChip U133 2.0 arrays were used to identify
genes differentially expressed in U937-AE cells compared to
U937-Mt. Samples were processed and data analyzed as
previously described ([24,27] and Text S1). Expression of 1,316
genes was regulated by AML1/ETO (Table S2): 592 genes (45%)
were upregulated and 724 (55%) downregulated. 50 genes were
selected for qPCR validation and confirmed microarray results in
90% of cases (Figure S3 and Table S3).
Cross-comparison between ChIP-chip and expression data led
to the identification of 358 genes with AML1/ETO peaks in their
promoter regions whose transcriptional levels change .1.5-fold
Author Summary
Acute myeloid leukemias (AML) are a group of hemato-
logic malignancies initiated by chromosomal abnormalities
that often give origin to oncogenic proteins with
transcriptional regulatory functions. These aberrant tran-
scription factors bind to specific sequences on DNA and
influence the activity of adjacent genes. The result is that
leukemic blasts display abnormalities in their gene
expression programs, which are ultimately responsible
for the malignant phenotype. In this study, genome-wide
approaches were exploited not only to identify target
genes, but also to discover interactions among different
transcription factors, with the aim of defining disease-
linked regulatory networks. We performed a detailed
analysis of the DNA binding pattern of an oncogenic
transcription factor, AML1/ETO, which is responsible for
approximately 10–15% of AML. We identified a specific
signature, which is characterized by the presence of
binding regions for AML1/ETO and for other transcription
factors, AML1 and HEB, and found that the DNA binding
pattern of AML1 and HEB is significantly affected in cells
expressing AML1/ETO. Our results, therefore, describe
genes regulated by AML1/ETO and demonstrate that this
oncogenic protein can significantly interfere with the
function of other transcriptional regulators.
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Figure 1. Identification of AML1/ETO binding regions in human promoters. (A) Expression of AML1/ETO protein in U937-AE cells treated for
8 hours with 100 mM ZnSO4 and in patient-derived SKNO-1 cells was investigated by Western blotting using an anti-AML1 antibody. U937-Mt cells
were used as negative control. The apparent difference in molecular weight between the two cell lines was due to the HA-tag domain. The two AML1
isoforms are also detected. Anti-tubulin antibody was used for normalization of protein levels. (B) 22 putative target genes were validated by qChIP in
U937-AE cells using anti-ETO (black bar) and anti-HA (dark grey bar) antibodies, and in SKNO-1 cells using the anti-ETO antibody. For U937-AE cells,
the light grey portion on each bar represents the level of enrichment in the U937-Mt cell line using the anti-HA antibody. In SKNO-1 cells, the mock
ChIP was performed using Protein G beads alone. The baseline (represented as a vertical black line on each graph) corresponds to the mean level of
enrichment obtained by qChIP on 8 negative control genes (see text and Figure S1). (C) Box-plot representing expression levels in AML samples of
AML1/ETO target genes identified by ChIP-chip and expression profiling (approximately 70% of these were included in the array used for the study
[28]). Seven representative clusters are shown, including the group of t(8;21) AML. The predominant chromosomal aberration or gene mutation
characterizing each cluster is reported below the graph (FLT3 mut, normal karyotype (NK), inv(16), t(15;17), t(8;21), CEBPa mut and t-MLL correspond
to clusters#2,#5,#9,#12,#13,#15, and#16, respectively, of the original study). White boxes represent expression levels of all genes on the array
(lower horizontal line is the median value), grey boxes indicate expression levels of AML1/ETO downregulated targets (higher horizontal line is the
median value in t(8;21) AML). (D) Functional pathways enriched in AML1/ETO target genes. The list of all AML1/ETO target genes (Table S1) and the
sub-groups of up-regulated and down-regulated genes (Table S4) were functionally annotated using DAVID, and clustered according to the KEGG
PATHWAY collection. The table reports categories significantly enriched in the three groups (p-value,0.05, False rate discovery ,10%), number of
genes retrieved in each pathway are also indicated.
doi:10.1371/journal.pgen.1000275.g001
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(Table S4), of which 247 (69%) downregulated and 111 (31%)
upregulated. Expression levels of these genes were then analyzed
in a dataset from 285 in vivo AML samples, including 22 patients
with t(8;21) [28]. This study had identified 16 groups of AML
patients on the basis of gene expression profiles, and the clustering
was correlated to the presence of specific chromosomal aberrations
and gene mutations [28]. The median expression level of genes
downregulated by AML1/ETO was significantly higher (p,0.001)
than the median level of other genes on the array (Figure 1C).
However, these genes were expressed at a significantly lower level
(p,0.05) in the t(8;21) cluster than in other AML clusters
(Figure 1C), suggesting they are repressed by the fusion protein
in vivo. The same analysis performed on the group of upregulated
genes revaled that their median expression level is also higher than
that of other genes (data not shown), but a comparative analysis
among different AML clusters could not be performed due to the
high variability in raw expression values and the small size of the
gene list. Taken together, these data suggest that AML1/ETO
preferentially binds to and regulates transcription of highly
expressed genes.
Functional classification of the 2,513 AML1/ETO target genes
according to KEGG molecular interaction networks (http://www.
genome.ad.jp/kegg/) [29] highlighted various pathways related to
functions of mature leukocytes, such as cytotoxicity, migration and
signaling. Interestingly, these were also over-represented in the
sub-group of repressed genes, while upregulated targets encoded
functions related to cell cycle and chronic myeloid leukemia
(Figure 1D and Table S5).
Sequence analysis of AML1/ETO binding regions revealed that
the AML1 consensus motif was significantly enriched only in the
promoters of downregulated genes (see Text S1 for details on
sequence analysis). Conversely, promoters of upregulated genes
were characterized by overrepresentation of binding sites for
transcription factors not related to myeloid differentiation.
AML1/ETO Binding Profile on Chromosome 19
AML1/ETO might influence gene expression by binding DNA
regions distant from the promoter. We, therefore, analyzed AML1/
ETO occupancy across a contiguous genomic region. Two replicas
of the Chr.19 Array were hybridized with ChIP products obtained
from the U937-AE and U937-Mt cell lines using the anti-HA and
anti-ETO antibodies (see Text S1 for data analysis) and 408
AML1/ETO binding peaks were identified (Table S6). The
Promoter Array had identified 148 AML1/ETO peaks on
chromosome 19; 130 of these were also retrieved with the Chr.19
Array, suggesting that the two platforms yield comparable results.
343/408 (84%) AML1/ETO peaks mapped to 254 known genes,
and can be further sub-localized as follows: 36% are within
promoters (defined as 24 kb to +1 kb from the TSS), 4% within
exons, 37% inside introns and 7% in 39 sequences in proximity of
the gene (Figure 2A). Of the 254 AML1/ETO target genes, 45%
have binding sites only in the 59 regulatory region, 46% have
binding sites only within the gene body (exons, introns or 39 region),
and 9% were bound both in the promoter and in the gene body.
The distribution of AML1/ETO peaks in U937-AE cells was
compared with that of histone mark H3K4me3, which consistently
associates with active promoters. ChIP products obtained with an
anti-H3K4me3 antibody on lysates of U937-AE cells were
hybridized to the Chr. 19 Array. H3K4me3 peaks clustered in
the proximity of TSS (Table S7), while AML1/ETO peaks
clustered both near TSS and in distant locations (.5 kilobases
downstream, Figure 2B), confirming that the fusion protein does
not bind exclusively to promoters.
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AML1/ETO binding outside of promoter regions may depend
on protein concentration. Increasing doses of ZnSO4 (10, 40 and
100 mM) were, therefore, used to titrate fusion protein levels, and
qChIP was performed on both promoter and downstream binding
sites in four of genes that present peaks in both locations
(Figure 2C). AML1/ETO binding was not homogeneous in the
Figure 2. Topography of AML1/ETO binding on chromosome 19. (A) AML1/ETO binding regions on chromosome 19: the pie plot shows the
percentage of AML1/ETO peaks in different gene locations. ‘‘Promoter+59’’ refers to the region comprised between 24 kb and +1 kb respect to the
TSS. ‘‘39’’ refers to the region comprised between the end of the last exon and 4 kb downstream. ‘‘Intergenic’’ refers to all regions that are neither
within a gene nor in a region defined as ‘‘promoter+59’’ or ‘‘39’’. Peaks that map in the proximity of transcripts that do not have a GeneBank ID but are
present in the EST database were classified as ‘‘EST’’. ‘‘Intergenic’’ refers to regions without any GeneBank ID or EST. (B) Distribution of AML1/ETO
peaks with respect to TSS of annotated genes. Upper panel: distribution of AML1/ETO peaks along the gene body. X-axis indicates the distance from
TSS (in kb), Y-axis shows the number of peaks inferred by PeakPicker software. Lower panel: distribution of H3K4me3 peaks, which map mainly within
1 kb from the TSS. (C) Four genes containing AML1/ETO peaks both in promoter and intragenic regions were analyzed for AML1/ETO binding at
different fusion protein concentrations. Western blot shows AML1/ETO protein levels in U937-AE cells treated with 10, 40, and 100 mM ZnSO4 for
8 hours. BCL3, VAV1, and UHRF1 have two AML1/ETO binding peaks (A = promoter, B = intragenic), whereas GNA15 has three peaks (A =promoter, B
and C= intragenic). For each gene, raw ChIP-chip data aligned to a scheme of the locus are shown above the graphs. AML1/ETO peaks are indicated
as A, B, or C, and their relative distances are reported. ChIP experiments were performed using the anti-HA antibody on U937-AE treated with ZnSO4
at the doses indicated below the graphs. Variations in relative enrichment do not depend on location of peaks.
doi:10.1371/journal.pgen.1000275.g002
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different gene locations: enrichment levels were higher in the
intragenic peaks of three genes (BCL3, VAV1 and UHRF1) and
lower in one gene (GNA15) (Figure 2C); however, AML1/ETO
protein levels did not affect the binding pattern.
AML1 Binding Profile on Chromosome 19
We next investigated if the binding profile of AML1/ETO
reflects that of the native AML1 transcription factor. A ChIP-chip
experiment was performed on the same cell lines using an anti-
AML1 antibody that does not cross-react with AML1/ETO, since
it recognizes the AML1 C-terminal portion, which is lost in the
fusion protein. ChIP products were hybridized to Chr.19 Arrays:
883 AML1 peaks were identified in U937-AE cells and 919 peaks
in U937-Mt cells (Table S8). 420 of the AML1 peaks were
common to both cell lines, demonstrating that 46% of AML1
binding sites remain occupied by AML1 after expression of the
fusion protein (Figure 3A).
The extent of overlap between AML1/ETO and AML1 binding
regions was quantified by comparing peak coordinates (Table S6
and Figure 3A–3B). Of the 408 AML1/ETO peaks identified on
Chr. 19, 83% (340/408) intercept AML1 peaks in U937-AE cells
(Figure 3A). Only 5% (21/408) of AML1/ETO binding occurs in
regions where AML1 was localized in U937-Mt cells but not in
U937-AE cells. These data suggest that AML1/ETO preferentially
binds to regions occupied by AML1 and does not function primarily
by displacing AML1 from its binding sites in vivo.
HEB Binding Profile on Chromosome 19
Detailed sequence analysis using both supervised and unsuper-
vised methods revealed a specific sequence signature associated
with genomic occupancy of AML1/ETO, which includes a
significant enrichment for AML1 and HEB binding sites (Text
S1). The finding that AML1/ETO binding regions often contain
the consensus motif for HEB is of particular interest, since HEB
associates with AML1/ETO in vivo [21]. The interaction of
endogenous HEB with AML1/ETO in U937-AE cells was
confirmed through co-immunoprecipitation experiments (Figure
S4) and the DNA binding pattern of HEB was investigated on the
Chr. 19 Array through ChIP-chip analysis using an anti-HEB
antibody. 903 HEB peaks were identified in U937-AE cells and
1023 peaks in U937-Mt cells (Table S9), and there was a massive
redistribution of HEB binding regions in cells expressing AML1/
ETO (Figure 4A–4B): in fact, only 288/1023 (28%) peaks
retrieved in U937-Mt cells are also identified U937-AE, and
615/903 (67%) of HEB peaks retrieved in U937-AE represent
novel binding sites.
Many HEB peaks in U937-AE cells coincide with AML1/ETO
binding regions: of the 408 AML1/ETO peaks, 285 (70%) are also
recognized by HEB (Table S6 and Figure 4A). To validate this
finding, qChIP was performed on 5 downregulated and 5
upregulated genes identified as AML1/ETO targets on the
Promoter Array. A significant increase of promoter-bound HEB
was detected, and enrichment levels were proportional to those of
AML1/ETO (Figure 4C). The correlation between AML1/ETO
and HEB binding was also investigated in SKNO-1 cells by qChIP
on 22 promoters (Figure S5). Enrichment of HEB was detected in
the same promoters bound by AML1/ETO (Figure 1B), confirm-
ing a significant correlation in the binding pattern of the two
transcription factors in AML cells expressing the fusion protein.
In the absence of AML1/ETO, HEB and AML1 localize to the
same genomic regions in approximately 25% of their global
binding sites, suggesting they may be involved in co-regulation of
common target genes (Text S1 and Figure S6). Interestingly,
AML1/ETO expression results in displacement of HEB and
AML1 from these common regions at lower frequency than in
genomic locations where these transcription factors do not co-
localize (Figure S6).
Correlation between AML1, HEB, and AML1/ETO Binding
Profiles and Gene Expression
The correlation between gene expression and DNA binding
pattern of AML1/ETO, AML1 and HEB was investigated by
Figure 3. AML1 binding pattern on chromosome 19. (A) Venn diagram representing the overlap of AML1 binding sites in U937-AE and U937-
Mt cells with AML1/ETO binding sites on chromosome 19. Physical overlaps .20% were considered significant. (B) Representative screenshot of
AML1 and AML1/ETO occupancy on chromosome 19. A window of 80 kb is shown. The two top lanes represent the AML1 binding profile in the
control cell line U937-Mt and in U937-AE, respectively. The two bottom lanes represent AML1/ETO binding patterns obtained with anti-HA and anti-
ETO antibodies. Asterisks indicate peaks identified by PeakPicker software.
doi:10.1371/journal.pgen.1000275.g003
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expression tiling. The Chr. 19 array was hybridized with RNA
derived from U937-Mt and U937-AE cells and expression levels of
the 1305 genes on chromosome 19 were calculated as described in
Text S1 (Table S10). The median expression value of the 254
genes associated with AML1/ETO peaks resulted significantly
higher than that of the remaining 1051 genes on chromosome 19
(Figure S7), confirming our previous observation that AML1/
ETO preferentially binds to genomic regions containing actively
transcribed genes (Figure 1C). Comparison of expression levels in
U937-AE and U937-Mt cells brought to the identification of 52
regulated genes (fold change .1.5, p-value,0.05). AML1/ETO
binds to genomic regions in the proximity of 24 of these (23
repressed, 1 induced). All of them were also associated with AML1
peaks and 23/24 with HEB peaks (Table S10). The remaining 28
regulated genes did not display AML1/ETO binding. However,
10 of these contain HEB binding regions in wild-type conditions,
and HEB is displaced in the presence of AML1/ETO (Figure S8).
Therefore, the expression level of HEB target genes can be
modified by AML1/ETO expression, suggesting that transcrip-
tional regulation determined by AML1/ETO may partly derive
from displacement of HEB from its native binding sites.
HEB Protein Levels Increase in AML1/ETO-Expressing
Cells
Our data suggest HEB may play a role in AML1/ETO-
dependent transcriptional regulation. However, not much is
known concerning HEB protein expression in the myeloid lineage.
The level of HEB protein in a series of leukemic cell lines of
myeloid origin, including AML1/ETO expressing cells, was
therefore investigated (Figure 5A). Notably, HEB is highly
expressed in AML1/ETO positive cell lines (SKNO-1 cells and
ZnSO4-induced U937-AE, Figure 5). Other cell lines, including
U937-Mt and a U937 clone expressing the ETO moiety of the
fusion protein (U937-ETO), display significantly less HEB protein
(Figure 5A). To exclude cell line specific effects, expression levels of
AML1/ETO and HEB were analyzed in U937-AE and U937 Mt
cells before and after induction with 100 mM ZnSO4 and
(Figure 5B). HEB protein levels were similar in the two uninduced
cell lines, and increased after ZnSO4 treatment only in U937-AE
cells. HEB mRNA levels were, instead, identical in U937-AE and
U937-Mt cells prior to and after ZnSO4 induction (Figure 5C),
suggesting that the increase in HEB protein is due to post-
translational regulatory mechanisms.
The effect of AML1/ETO expression on HEB protein levels
was confirmed in a different cellular context. Co-transfection of
HeLa cells with PINCO-AML1/ETO and pCDNA3.1-FLAG-
HEB expression vectors showed that HEB protein levels were
significantly higher than in control cells transfected with
pCDNA3.1-FLAG-HEB and PINCO (Figure 5D). This effect is
not mediated by induction of pCDNA3.1-driven transcription,
since expression levels of other genes inserted into the same vector
were not affected by co-expression with PINCO-AML1/ETO
(Figure 5D). To exclude artifacts due to differences in transfection
efficiency, PINCO-AML1/ETO was co-transfected with both
pCDNA3.1-FLAG-HEB and pCDNA3.1-ZNF384 (Figure 5E).
Only HEB protein levels were higher in cells expressing AML1/
Figure 4. HEB binding pattern on chromosome 19. (A) Venn diagram representing the overlap of HEB binding sites in U937-AE and U937-Mt
cells with AML1/ETO binding sites on chromosome 19. Regions with at least 20% physical overlap were considered significant. (B) Screenshots of HEB
and AML1/ETO occupancy on chromosome 19. Three representative regions show the displacement of HEB upon expression of AML1/ETO and
highlight the similarity of the binding patterns of the two proteins in U937-AE cells. The two top lanes represent HEB binding profile in U937-Mt and
in U937-AE. The two bottom lanes represent AML1/ETO binding patterns obtained with anti-HA and anti-ETO antibodies. Asterisks indicate peaks
identified by PeakPicker software. (C) qChIP with an anti-HEB antibody analyzing the promoter of 10 genes regulated by AML1/ETO (5
downregulated: NFE2, HCK, OGG1, CD244, and ITGAM; and 5 upregulated: CDKN1B, HOXA1, CAV1, CDKN1A, and CD48) shows increased amounts of
HEB in U937-AE (left graph). Right graph shows ChIP analysis of AML1/ETO protein on the same regions.
doi:10.1371/journal.pgen.1000275.g004
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ETO, while ZNF384 levels were not significantly affected by the
fusion protein.
The correlation between AML1/ETO and HEB protein levels
was next analyzed in primary cells from AML mouse models. HEB
protein is not detected in wild-type bone marrow cells, or in
normal splenocytes (Figure 5F). Leukemic blasts from AML1/
ETO mice expressed significant levels of HEB (Figure 5F), as
opposed to blasts from PML/RARa transgenic mice, which
provide another model of AML. These data enforce the idea that
HEB plays a role selectively in t(8;21) leukemia.
Although total bone marrow cells did not express HEB
(Figure 5F), the more undifferentiated fraction (Lin2 cells) had a
detectable, albeit low, amount of HEB protein, as opposed to the
more abundant Lin+ differentiated cells (Figure 5G). This result
suggests that HEB might be present only in a subset of early
progenitors.
Figure 5. HEB protein levels increase in AML1/ETO-expressing cells. (A) Expression of HEB protein in a panel of human myeloid cell lines:
30 mg of total cell lysates were analyzed by Western blot with an anti-HEB antibody. AML1/ETO positive cells (U937-AE and SKNO-1) express higher
levels of HEB. U937 cell lines were induced with ZnSO4 for 24 hours. An anti-actin antibody was used for normalization of protein levels. (B) U937-AE
cells were treated for 8 and 24 hours with 100 mM ZnSO4. AML1/ETO protein levels peak after 8 hours. HEB protein levels increase after AML1/ETO
expression. No modification in HEB levels is detectable after ZnSO4induction of control U937-Mt cells. (C) HEB mRNA levels in U937-AE and U937-Mt
cells prior to and after 8 hours of 100 mM ZnSO4 treatment are shown (GAPDH normalized). AML1/ETO does not modify the levels of HEB transcript.
(D) HEB protein levels in HeLa cells increase when pCDNA3.1-FLAG-HEB is co-transfected with PINCO-AML1/ETO expression vector. This effect is not
seen after co-transfection of AML1/ETO with other genes cloned into the same vector (pCDNA3.1-FLAG). All proteins were revealed by anti-FLAG
immunoblot. (E) Co-transfection of PINCO-AML1/ETO with both pCDNA3.1-FLAG-HEB and pCDNA3.1-FLAG-ZNF384 results in a specific increase of
HEB protein levels. (F) Expression of HEB protein in mouse tissues. HEB is not detected in wild-type murine bone marrow or spleen. AML blasts
derived from the spleens of AML1/ETO transgenic mice express HEB, whereas blasts from PML/RARa transgenics do not. (G) HEB protein levels were
analyzed in total bone marrow, Lin2 and Lin+ cellular compartments form wild-type mice. Detectable levels of HEB are found only in the Lin2
fraction of murine bone marrow.
doi:10.1371/journal.pgen.1000275.g005
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Discussion
The analysis of transcription factor binding patterns using genome-
wide approaches can serve not only to identify direct target genes, but
also to discover interactions among transcription factors that could
help in defining disease-linked regulatory networks. We investigated
the genome-wide binding profile of AML1/ETO at human
promoters and in a contiguous genomic region, and its correlation
with AML1 and HEB, with the aim of understanding the
determinants of its transcriptional regulatory function.
In U937 cells, AML1/ETO binds to the promoter regions of
2,513 non-redundant genes, and causes transcriptional changes in
358 of them. Of these, 70% are repressed, including many genes
involved in neutrophilic/myeloid differentiation (i.e. MPO, HCK,
FYN, GADD45B, ITGAM, ITGB2). On the other hand, 30% of
target genes are induced, including HOX genes (HOXA10, HOXA5,
HOXC6) and the cell cycle regulators CDKN1A and CDKN1B.
CDKN1A is of particular interest since it is know to regulate
maintenance of quiescent hematopoietic stem cells [30] and also
modulates leukemic development in mouse models of t(8;21) ([31],
PG Pelicci, subitted for publication). The AML1 consensus
sequence is only enriched in downregulated genes, whereas
upregulated genes show enrichment in binding sites for other
transcription factors. Therefore, a proportion of AML1/ETO
binding to DNA may be achieved independently from the AML1
motif recognition.
AML1/ETO has been hypothesized to function as dominant
negative of its wild type component AML1 [13–15]. Analysis of the
DNA binding pattern of AML1 showed that the two transcription
factors often bind to the same DNA regions. In many cases AML1/
ETO target genes represent native AML1 targets, but the presence
of the fusion protein does not displace the wild-type protein. In
other cases, the two proteins are present in genomic regions where
AML1 is normally not found. Therefore, although the two proteins
do not physically associate (data not shown), AML1/ETO
expression is capable of driving AML1 to new sites on the genome,
perhaps by rendering them accessible. The functional consequences
of the co-localization of AML1 and AML1/ETO on transcriptional
regulation remain to be elucidated.
The E-protein HEB has been described as an interactor of both
AML1/ETO and ETO [21]. It was hypothesized that through this
interaction, AML1/ETO could be redirected to E-protein target
genes, possibly deregulating their expression. We found that the
binding pattern of HEB in U937 cells is disrupted upon expression
of AML1/ETO, and the fusion protein recruits HEB to its binding
regions. Co-occurrence of HEB and AML1/ETO in promoters was
also detected in the SKNO-1 cell line, demonstrating that this
phenomenon is not peculiar to the cellular system under analysis.
The specific repositioning of HEB to AML1/ETO binding sites is
also supported by sequence analysis, which identifies the AML1
motif in HEB binding regions only in cells expressing AML1/ETO.
More information concerning the complexity of AML1/ETO
binding can be obtained by looking simultaneously at the binding
patterns of AML1 and HEB in the presence and absence of
AML1/ETO. The first observation is that these two transcription
factors share a proportion of target genes in wild-type conditions,
pointing to common regulatory functions in hematopoiesis. When
they bind to common target sites, AML1 and HEB are less prone
to be displaced by AML1/ETO expression, and these regions
represent preferential binding sites for the fusion protein.
Furthermore, regulation of gene expression by AML1/ETO is
significantly associated with the co-occurrence of AML1 and HEB,
suggesting that common binding regions for the three transcription
factors are of relevance to AML1/ETO function.
A proportion of genes regulated by AML1/ETO did not display
binding of the fusion protein in proximity of the gene. Our results
demonstrate that some of these genes contain regions bound by
HEB in wild-type conditions, and that this binding was no longer
present in cells expressing AML1/ETO. Therefore, indirect
transcriptional regulation determined by AML1/ETO may be
partially due to displacement of HEB from its native target genes,
and interference with HEB-dependent gene expression.
In the hematopoietic system, HEB has been studied in lymphoid
differentiation: loss of function experiments have shown that HEB
is relevant in the early stages of B-cell and T-cell development
[32]. We show that HEB is expressed in the Lin2 compartment of
murine bone marrow, and is absent in more differentiated myeloid
cells. HEB expression appears to be necessary for survival of cells
expressing the fusion protein (A. Gardini and M. Alcalay,
unpublished), suggesting that the translocation may only be viable
in cells that express HEB, such as early progenitors or stem cells.
Furthermore, HEB protein levels increase in the presence of
AML1/ETO, whereas HEB mRNA levels remain unchanged,
implying that expression of the fusion protein is associated with
stabilization of HEB through unknown post-translational mecha-
nisms. Therefore, it is possible that the HEB-expressing subpop-
ulation of progenitor/stem cells might contain the target cell for
AML1/ETO, which would then expand the compartment of
HEB-expressing cells and sustain HEB protein levels by modulat-
ing post-translational regulatory mechanisms.
Our study represents the first comprehensive analysis of AML1/
ETO global genomic occupancy and provides a correlation to its
effect on gene expression. Our results point to a pivotal role for
AML1 and HEB in t(8;21) myeloid leukemogenesis.
Materials and Methods
Cell Lines
The U937 AML1/ETO-HA#9 clone (U937-AE) was generat-
ed by stable transfection of AML1/ETO-HA cDNA cloned in the
inducible pSG-MtNEO plasmid vector as already described [24].
The U937 ETO#15 clone (U937-ETO) carries the cDNA portion
of ETO retained in the fusion gene in pSG-MtNEO (M. Alcalay
and P.G. Pelicci, unpublished). A bulk population of U937 cells
transfected with the empty pSG-MtNEO vector (U937-Mt) was
used as control. Cell lines were treated for 8 hours with 100 mM
ZnSO4 to allow expression of the transgene.
U937-AML1/ETO9a cells (U937T-AE9a) were generated by
stable transfection of U937T cells [33] with HA-tagged AML1/
ETO9a cloned in the inducible pUHD10.3 tet-off vector. Cells
were grown in the presence of 1 mg/ml tetracyclin. HA-AE9a
induction was reached after 24 h of tetracyclin withdrawal.
U937 cells were grown in RPMI-1640 supplemented with 10%
FCS and 2 mM glutamine at 37uC in a humidified atmosphere
containing 5% CO2. HeLa cells were grown in DMEM medium
supplemented with 10% FCS and 2 mM glutamine. Myeloid cell
lines used for Western Blotting were grown according to standard
procedures.
Antibodies
Immunopurified anti-HA from clone 12CA5 was used against
AML1/ETO. Commercially available antibodies against ETO
(Santa Cruz sc-9737), AML1/RUNX1 (Abcam ab23980), HEB
(Santa Cruz sc-357), H3K4me3 (Abcam ab8580) were used in ChIP
assay and Western blot. The anti-AML1/RHD (Oncogene PG285)
antibody, recognizing both wild-type AML1 and AML1/ETO,
anti-alpha-tubulin (SIGMA T9026), anti-vinculin (SIGMA V9131)
and anti-actin (SIGMA A4700) were used for Western blotting.
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Chromatin Immunoprecipitation
Cells were cross-linked with 1% formaldehyde for 10 minutes at
room temperature, harvested and washed twice with 16 PBS.
Pellet was resuspended in ChIP lysis buffer (150 mM NaCl, 1%
Triton-X 100, 0,1% SDS, 500 mM DTT, 10 mM Tris-HCl,
5 mM EDTA) and sonicated to obtain an average chromatin
length of 500 bp. 56106 cells were used for each IP and incubated
at 4uC overnight with the antibody of interest previously coated on
Dynabeads Protein A magnetic beads (Invitrogen, USA). For anti-
ETO ChIP, Protein G Sepharose beads were used (Zymed, USA).
Beads were then washed twice with each of the following
buffers: Mixed Micelle Buffer (150 mM NaCl, 1% Triton-X 100,
0,2% SDS, 20 mM Tris-HCl, 5 mM EDTA, 65% sucrose), LiCl/
detergent wash (250 mM LiCl, 0.5% Na deoxycholate, 0,5% NP-
40, 10 mM Tris-HCl, 1 mM EDTA), Buffer 500 (500 mM NaCl,
% Triton-X 100, 0.1% Na deoxycholate, 25 mM HEPES, 10 mM
Tris-HCl, 1 mM EDTA) an a final wash was performed with 16
TE. Finally, beads were resuspended in 16 TE containing 1%
SDS and incubated at 65uC for 10 minutes to elute immunocom-
plexes. Elution was repeated twice, and the samples were further
incubated overnight at 65uC to reverse cross-linking, along with
the untreated input (2,5% of the starting material). After treatment
with 0,5 mg/ml proteinase K for 3 hours, DNA was purified with
Wizard SV Gel and PCR Clean-up system (Promega, USA)
according to manufacturer’s protocol and eluted in nuclease-free
water. ChIP products and input DNA were used for quantitative
PCR or further treated for ChIP-chip.
ChIP-chip
The NimbleGen Systems Human HG17 Promoter Array set
from NimbleGen catalogue, which contains .700,000 probes
exploring 4 kb upstream and 1 kb downstream of 24,434
annotated genes, were used for genome-wide identification of
AML1/ETO binding sites. In addition, custom designed high-
density oligonucleotide arrays, containing ,360,000 isothermal
probes (from 50 to 60 bp long) contiguously tiled along
chromosome 19, were produced by NimbleGen Systems (Madi-
son, Wisconsin, USA). Non-repetitive sequences of chromosome
19 available from UCSC Hg.17 were used for the probe design.
ChIP products were obtained as described above. 80% of a
single ChIP product and 40 ng of the input were further treated
for array hybridization as described by Kim et al. [34]. Briefly,
samples were blunt-ended then ligated to the annealed linker
oligonucleotides JW102: GCGGTGACCCGGGAGATCT-
GAATTC and JW103: GAATTCAGATC. DNA was amplified
in a 1st LM-PCR reaction using oligo JW102 and Phusion DNA
Polymerase (FynnZyme, Oy, Finland), and PCR products were
purified with Wizard SV Gel and PCR Clean-up system. 200 ng
were used as template in a 2nd LM-PCR. 4 mg of purified DNA
were labelled by NimbleGen Services using random priming and
Cy3/Cy5 fluorescent dyes. Input DNA and ChIP DNA were
labeled with different fluorophores and co-hybridized on the same
array. For every probe, results were rated as log2 (ratio ChIP/
input). Labeling and hybridization were performed by NimbleGen
Services, Reykjavik, Iceland. Data were visualized and images
extracted using SginalMap software (NimbleGen Systems).
ChIP-chip Data Analysis
A perl script called PeakPicker (M. Cesaroni et al, manuscript
submitted) was developed as a tool to perform peak analysis on
different types of ChIP-chip platforms. Briefly, PeakPicker
identifies binding regions (peaks) by centering a sliding window
of user-defined size around every probe of the array, then picking
out the number of probes within the window that are above a
given percentile (see Text S1). For the analysis of Promoter Array
data, since probes are more sparse (110 bp interval), a lower
stringency analysis was used: 90th percentile, window of 1000 bp,
|log(p-value)|.2. For the analysis of Chr.19 Array data, stringent
parameters were applied: 98th percentile, window of 500 bp,
|log(p-value)|.7.
PeakPicker generates a tab file representing a list of binding
peaks sorted by their first and last nucleotide mapped on UCSC
Hg.17. Comparison between two lists of peaks is obtained by
measuring the percentage of physical overlap. Peaks with at least
20% physical overlap are considered co-occurrent. To generate
the high stringency list of 408 AML1/ETO binding peaks on
Chr.19, we compared anti-ETO and anti-HA lists using a
threshold of 60% peak overlap.
qPCR Analysis of ChIP Samples
All reactions were performed with the following reagents:
0.4 mM of each primer, 12.5 ml of SYBR Green PCR Master
MIX (Applera, USA), and a fixed volume of template DNA in a
final volume of 25 ml. Thermal cycling parameters were:
2 minutes at 50uC, followed by 10 minutes at 95uC, followed by
40 cycles of 15 seconds at 95uC, and 1 minute at 60uC. We used
1/40 of the eluted DNA from both ChIP samples and input.
Oligonucleotides were designed to validate regions occupied by
AML1/ETO according to bioinformatics analysis of NimbleGen
Promoter Array (see Text S1 for oligo sequences). The amount of
immunoprecipitated DNA relative to that present in total input
chromatin was calculated as described by [26].
RNA Extraction, Affymetrix GeneChip Hybridization, and
Analysis
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN,
Valencia, California, USA). For each of the U937 cell lines (AE and
Mt), three independent RNA extractions were performed, and an
equal quantity of each of the three RNA preparations was then
mixed to generate an RNA pool for each sample.
RNA pools were labeled and hybrydized to the Affymetrix HG-
U133 Plus 2.0 array (Affymetrix, USA). Results derived from
U937-AE cells (sample) were compared to results from U937-Mt
(baseline) cells by ‘‘comparative analysis’’ with GCOS software.
Data were then analyzed using GenePicker software [35] as
previously described [24], using a fold change cutoff.1.5 and a p-
value of 0.05. For details on Affymetrix data generation and
processing see Text S1.
50 regulated genes were chosen for validation by qRT-PCR on
an independent set of RNAs. qPCR was performed as already
described for ChIP samples, using 15 ng of cDNA reverse
transcribed with Super Script III (Invitrogen, USA) according to
manufacturer’s protocol (see Table S3 for primer sequences).
Functional Classification of AML1/ETO Target Genes
Functional classification was performed starting from the list of
AML1/ETO target genes (Table S1) and the sub-group of
regulated genes (Table S4). Gene lists were functionally annotated
using DAVID (http://david.abcc.ncifcrf.gov) [36], and clustered
according to the KEGG PATHWAY collection [29].
Co-Immunoprecipitation
U937-AE and U937-Mt were treated with 100 mM ZnSO4,
collected and resuspended in CoIP buffer (20 mM Tris HCl
pH 7.5, 300 mM NaCl, 1% Triton, 20% Glycerol, 1 mM EDTA,
1 mM EGTA, 2.5 mM Na Pyrophosphate, 0.5 mM DTT). After
brief sonication, lysates were cleared by centrifugation at
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13,000 rpm and incubated with the indicated antibody and
Protein A sepharose beads (Bio-Rad, Hercules, California, USA).
Immunoprecipitates were washed 4 times in the CoIP buffer,
eluted and separated by electrophoresis on denaturing SDS-
PAGE. Immunoblotting was performed according to standard
procedures.
Mouse Cell Lysates
Bone marrow cells were harvested from 8- to 10-week-old
129SvEv mice and treated for purification of undifferentiated cells
(Lin2). After centrifugation through a Ficoll gradient, mononu-
cleated cells were enriched for progenitors by affinity depletion of
cells presenting myeloid, erythroid, and lymphoid differentiation
markers using commercially available reagents (Stem Cell
Technologies, Vancouver, BC, Canada). Depleted cell were also
collected as the differentiated subpopulation (Lin+).
Leukemic mice were generated by retroviral transduction of
PINCO-AML1-ETO or PINCO-PML/RAR into Lin2 cells, as
described [37]. Briefly, Lin2 cells were infected in 24-multiwell
plates coated with retronectin. GFP-positive cells were FACS-
sorted (FACSVantage instrument, BD) and reinoculated into
lethally irradiated (10 Gy) syngeneic mice (26105 Lin2/mouse).
After 4 weeks, animals transduced with AML1/ETO expressing
cells were treated with N-ethyl-N-nitrosourea (50 mg/kg), as
described [38]. AML blasts cells were harvested from the spleens
of leukemic animals (with .80% infiltration of leukemic cells) by
centrifugation through Ficoll gradient, and lysed for Western blot
analysis.
HEB Cloning and Transfection Assays
The full-length HEB isoform (RefSeq accession number:
NM_207036) was isolated from U937 cells by PCR amplification
of cDNA, using the following primers: f-ATGGATCC-
TAATCCCCAGCAACAACGC (contains an additional BamHI
protruding 59 tail) and r- ATCTCGAGTTACATATGACCCA-
TAGG (contains an additional Xho protruding 59 tail). PCR
reactions were run on an agarose gel, extracted, purified and
inserted into BamHI-Xho digested pCDNA3.1 (Invitrogen), which
contains an in-frame FLAG tag sequence at the 59.
A FLAG-pCDNA3.1 vector containing full length ZNF384 was
also generated by PCR-cloning using f-ATGGTACCAGAA-
GAATCTCACTTC and r-ATGAATTCCTAAGAGCTGGC-
CAGG primers. FLAG-pCDNA3.1 vectors containing SMYD2
and EPN3 were a gift from Bruno Amati and Pier Paolo Di Fiore,
respectively. PINCO and PINCO-AML1/ETO vectors used in
the co-transfection studies were already published [39].
Transfection in HeLa cells was performed using Lipofectamine
(Invitrogen) and 500 ng of each plasmid (1 well in a 6-well plate),
diluted in serum-free DMEM culture medium. Cells were
collected and lysed for Western Blotting 24 hours after transfec-
tion.
Accession Numbers
Microarray data included in this manuscript have been
deposited in GEO, (http://www.ncbi.nlm.nih.gov/geo/), and
can be retrieved as Data Series with accession number GSE10537.
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